Technical Analysis for BYSI - BeyondSpring, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | 5.99% | |
| Pocket Pivot | Bullish Swing Setup | 5.99% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 16 hours ago |
| Rose Above Upper Bollinger Band | about 16 hours ago |
| Up 5% | about 16 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/18/2024
BeyondSpring, Inc. Description
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.0 |
| 52 Week Low | 0.6534 |
| Average Volume | 177,175 |
| 200-Day Moving Average | 1.39 |
| 50-Day Moving Average | 2.63 |
| 20-Day Moving Average | 2.29 |
| 10-Day Moving Average | 2.46 |
| Average True Range | 0.26 |
| RSI (14) | 62.83 |
| ADX | 17.22 |
| +DI | 31.02 |
| -DI | 19.58 |
| Chandelier Exit (Long, 3 ATRs) | 2.15 |
| Chandelier Exit (Short, 3 ATRs) | 2.50 |
| Upper Bollinger Bands | 2.79 |
| Lower Bollinger Band | 1.79 |
| Percent B (%b) | 1.04 |
| BandWidth | 43.80 |
| MACD Line | 0.07 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.078 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.22 | ||||
| Resistance 3 (R3) | 3.21 | 3.06 | 3.16 | ||
| Resistance 2 (R2) | 3.06 | 2.96 | 3.07 | 3.13 | |
| Resistance 1 (R1) | 2.95 | 2.90 | 3.01 | 2.96 | 3.11 |
| Pivot Point | 2.80 | 2.80 | 2.83 | 2.81 | 2.80 |
| Support 1 (S1) | 2.69 | 2.70 | 2.75 | 2.70 | 2.55 |
| Support 2 (S2) | 2.54 | 2.64 | 2.55 | 2.53 | |
| Support 3 (S3) | 2.43 | 2.54 | 2.51 | ||
| Support 4 (S4) | 2.44 |
